Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
155.50
+2.39 (1.56%)
Nov 21, 2024, 4:00 PM EST - Market closed

Company Description

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.

The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.

this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery.

It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics.

The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis.

Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson
Johnson & Johnson logo
Country United States
Founded 1886
IPO Date Sep 24, 1944
Industry Drug Manufacturers - General
Sector Healthcare
Employees 131,900
CEO Joaquin Duato

Contact Details

Address:
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
United States
Phone 732 524 0400
Website jnj.com

Stock Details

Ticker Symbol JNJ
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000200406
CUSIP Number 478160104
ISIN Number US4781601046
Employer ID 22-1024240
SIC Code 2834

Key Executives

Name Position
Joaquin Duato Chief Executive Officer and Chairman
Joseph J. Wolk CPA Executive Vice President and Chief Financial Officer
Dr. Peter M. Fasolo Ph.D. Executive Vice President and Chief Human Resources Officer
Jennifer L. Taubert Executive Vice President and Worldwide Chairman of Innovative Medicine
Dr. John C. Reed M.D., Ph.D. Executive Vice President of Innovative Medicine, Research & Development
Robert J. Decker Jr. Controller and Chief Accounting Officer
James Swanson Executive Vice President and Chief Information Officer
Jessica Moore Vice President of Investor Relations
Dirk Brinckman Chief Compliance Officer
Dr. Guy J. Lebeau M.D. Group Chairman of MD&D Business - EMEA

Latest SEC Filings

Date Type Title
Nov 13, 2024 13F-HR Quarterly report filed by institutional managers, holdings
Nov 6, 2024 25-NSE Filing
Oct 23, 2024 10-Q Quarterly Report
Oct 15, 2024 8-K Current Report
Sep 20, 2024 8-K Current Report
Sep 10, 2024 8-K Current Report
Aug 30, 2024 144 Filing
Aug 29, 2024 N-PX Annual Report of proxy voting record of management investment companies
Aug 26, 2024 8-K Current Report
Aug 9, 2024 13F-HR Quarterly report filed by institutional managers, holdings